Literature DB >> 22410860

Dying of hematologic patients--treatment characteristics in a German University Hospital.

Patrick Brück1, Malgorzata Pierzchlewska, Marta Kaluzna-Oleksy, Maria Elizabeth Ramos Lopez, Mathias Rummel, Dieter Hoelzer, Angelika Böhme.   

Abstract

The treatment of hematologic patients in palliative situations remains a major challenge as there are special clinical needs, e.g., transfusions and the high risk for infectious complications with subsequent use of broad anti-infective treatment. Furthermore, most hematologic patients have a relatively long history of disease and are acquainted with "their" wards; that is why most are treated on these hematologic and not on specialized palliative wards. The standardized approach to the care of hematologic patients with curative treatment intention is probably not fully appropriate for palliative patients. In order to evaluate the current situation of treatment characteristics in a German university hospital, we retrospectively evaluated the medical documentation of all patients who died on a hematologic ward between 2005 and 2008. While we found a high number of chemotherapeutic, anti-infective, analgesic, and sedative treatments, of transfusions, of treatment on the intensive care units, and of invasive nature, non-somatic interventions were rather scarce. Symptom control, e.g., for bleeding events or pain, was frequently not adequately achieved. With regard to the palliative situation, a holistic approach with the maintenance of patients' autonomy and the preference for dying at home, the treatment of hematologic patients in a palliative situation has to be reconsidered.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22410860     DOI: 10.1007/s00520-012-1417-8

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  32 in total

1.  Sedative use in the last week of life and the implications for end-of-life decision making.

Authors:  Nigel Sykes; Andrew Thorns
Journal:  Arch Intern Med       Date:  2003-02-10

2.  Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.

Authors:  Utz Krug; Christoph Röllig; Anja Koschmieder; Achim Heinecke; Maria Cristina Sauerland; Markus Schaich; Christian Thiede; Michael Kramer; Jan Braess; Karsten Spiekermann; Torsten Haferlach; Claudia Haferlach; Steffen Koschmieder; Christian Rohde; Hubert Serve; Bernhard Wörmann; Wolfgang Hiddemann; Gerhard Ehninger; Wolfgang E Berdel; Thomas Büchner; Carsten Müller-Tidow
Journal:  Lancet       Date:  2010-12-03       Impact factor: 79.321

3.  Characteristics of deaths in a department of oncohaematology within a general hospital. A study of 81 cases.

Authors:  F Bauduer; C Capdupuy; M Renoux
Journal:  Support Care Cancer       Date:  2000-07       Impact factor: 3.603

Review 4.  Pain in malignant hematology.

Authors:  Pasquale Niscola; Andrea Tendas; Laura Scaramucci; Marco Giovaninni; Luca Cupelli; Vitaliana De Sanctis; Gregorio Antonio Brunetti; Francesco Bondanini; Roberto Palumbo; Michela Lamanda; Roberta Battistini; Claudio Cartoni; Claudio Romani; Edoardo Arcuri
Journal:  Expert Rev Hematol       Date:  2011-02       Impact factor: 2.929

5.  The final phase in acute myeloid leukaemia (AML). A study on bleeding, infection and pain.

Authors:  Ann Marie Stalfelt; Håkan Brodin; Solveig Pettersson; Anna Eklöf
Journal:  Leuk Res       Date:  2003-06       Impact factor: 3.156

6.  Chemotherapy use among Medicare beneficiaries at the end of life.

Authors:  Ezekiel J Emanuel; Yinong Young-Xu; Norman G Levinsky; Gail Gazelle; Olga Saynina; Arlene S Ash
Journal:  Ann Intern Med       Date:  2003-04-15       Impact factor: 25.391

7.  A history of cancer chemotherapy.

Authors:  Vincent T DeVita; Edward Chu
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

Review 8.  Intensify, resuscitate or palliate: decision making in the critically ill patient with haematological malignancy.

Authors:  Quentin A Hill
Journal:  Blood Rev       Date:  2009-11-13       Impact factor: 8.250

9.  Cancer patients' perceptions of their disease and its treatment.

Authors:  W J Mackillop; W E Stewart; A D Ginsburg; S S Stewart
Journal:  Br J Cancer       Date:  1988-09       Impact factor: 7.640

10.  Sedation in palliative care - a critical analysis of 7 years experience.

Authors:  H Christof Muller-Busch; Inge Andres; Thomas Jehser
Journal:  BMC Palliat Care       Date:  2003-05-13       Impact factor: 3.234

View more
  5 in total

Review 1.  A systematic review of prognostic factors at the end of life for people with a hematological malignancy.

Authors:  Elise Button; Raymond Javan Chan; Shirley Chambers; Jason Butler; Patsy Yates
Journal:  BMC Cancer       Date:  2017-03-23       Impact factor: 4.430

2.  A qualitative evidence synthesis of healthcare professionals' experiences and views of palliative care for patients with a haematological malignancy.

Authors:  Maura Dowling; Paul Fahy; Catherine Houghton; Mike Smalle
Journal:  Eur J Cancer Care (Engl)       Date:  2020-09-09       Impact factor: 2.520

3.  Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany.

Authors:  Inna Dabisch; Jürgen Dethling; Charalabos-Markos Dintsios; Melanie Drechsler; Daniel Kalanovic; Peter Kaskel; Frank Langer; Jörg Ruof; Thorsten Ruppert; Daniel Wirth
Journal:  Health Econ Rev       Date:  2014-01-24

4.  End-of-Life Trajectories of Patients With Hematological Malignancies and Patients With Advanced Solid Tumors Visiting the Emergency Department: The Need for a Proactive Integrated Care Approach.

Authors:  Mary-Joanne Verhoef; Ellen J M de Nijs; Claudia S Ootjers; Marta Fiocco; Anne J Fogteloo; Christian Heringhaus; Corrie A M Marijnen; Nanda Horeweg; Yvette M van der Linden
Journal:  Am J Hosp Palliat Care       Date:  2019-12-23       Impact factor: 2.500

5.  Preferred and actual place of death in haematological malignancy.

Authors:  D A Howell; H I Wang; E Roman; A G Smith; R Patmore; M J Johnson; A Garry; M Howard
Journal:  BMJ Support Palliat Care       Date:  2015-07-08       Impact factor: 3.568

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.